News from janssen pharmaceutical companies A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 06, 2021, 07:00 ET New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients

Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than...

Feb 03, 2021, 16:10 ET REVEAL Lite 2 Risk Calculator Offers Simplified Model to Assess One-Year Mortality Risk Status in Patients with Pulmonary Arterial Hypertension (PAH)

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from an analysis determining the validity of the Registry to...

Sep 30, 2020, 07:00 ET Janssen Submits New Drug Application (NDA) to U.S. FDA for UPTRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug...

May 29, 2020, 08:24 ET Janssen Highlights Innovative Oncology Portfolio and Pipeline of Oral, Biologic and Cell Therapies Through ASCO20 Virtual Scientific Program

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the latest research from its innovative oncology portfolio and pipeline of...

Dec 14, 2018, 08:36 ET Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental New Drug Application (sNDA) for XARELTO®...

Jun 24, 2018, 10:00 ET Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced late-breaking results of a new real-world analysis of more than 700,000 U.S....

Jun 23, 2018, 10:00 ET Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new findings from two real-world studies comparing sodium glucose...

Jun 08, 2018, 08:30 ET New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association's 78th Annual Scientific Sessions

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a new late-breaking analysis (OBSERVE-4D) examining how INVOKANA®...

Jun 04, 2018, 09:00 ET TREMFYA® (guselkumab) Study Indicating The Significance Of Inhibiting IL-23 Pathway In Adults With Psoriatic Arthritis Published In The Lancet

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced results from a Phase 2 study that were published in The Lancet...

May 18, 2018, 05:50 ET ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson today presented a post-hoc analysis from the Phase 3 SPARTAN study that showed treatment...

Apr 27, 2018, 08:30 ET Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the results of a real-world study showing that adults with type 2 diabetes...

Apr 16, 2018, 04:15 ET Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that it has entered a new worldwide collaboration with Bristol-Myers Squibb ...

Mar 11, 2018, 04:45 ET INVOKANA® (canagliflozin) Significantly Reduces the Risk of Heart Failure-Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new analysis showing that INVOKANA® (canagliflozin)...

Mar 10, 2018, 12:15 ET New Late-Breaking Study Finds Wearable Electrocardiogram (ECG) Monitoring Patch Can Detect Atrial Fibrillation Earlier and More Efficiently than Routine Care

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced late-breaking results of a new home-based clinical trial showing that a...

Feb 26, 2018, 08:30 ET New Late-Breaking XARELTO® (rivaroxaban) and INVOKANA® (canagliflozin) Data to be Presented at the American College of Cardiology's Annual Scientific Session

New studies and late-breaking analyses from the Janssen Pharmaceutical Companies of Johnson & Johnson are among the 11 company abstracts accepted for ...

Feb 21, 2018, 08:00 ET New Real-World Analysis Published in The Journal of Clinical Psychiatry Illuminates the Significant Economic Toll of Treatment-Resistant Depression on Individuals, Employers and Payers

New real-world findings published in The Journal of Clinical Psychiatry expand on the growing evidence that people with treatment-resistant...

Feb 16, 2018, 10:00 ET New TREMFYA® (guselkumab) Data Demonstrates Long-Term Skin Clearance In Patients With Moderate To Severe Plaque Psoriasis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe...

Feb 08, 2018, 08:11 ET ZYTIGA® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new...

Feb 07, 2018, 07:30 ET Janssen Enters Into Worldwide Collaboration With Theravance Biopharma For Oral, Pan-JAK Inhibitor Drug Candidate For The Treatment Of Inflammatory Bowel Disease

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today their entry into a worldwide collaboration with an affiliate of Theravance...

Jan 25, 2018, 08:04 ET Janssen to Present 14 Abstracts in Prostate and Urothelial Cancers at ASCO GU 2018, Including New Data on Apalutamide (ARN-509), ZYTIGA® (abiraterone acetate) and Erdafitinib

New data from the Janssen Pharmaceutical Companies of Johnson & Johnson will be presented at the American Society of Clinical Oncology Genitourinary...

Jan 16, 2018, 08:30 ET FDA Mini-Sentinel Assessment Confirms Safety and Effectiveness of XARELTO® (rivaroxaban) and its Association with a Lower Risk of Ischemic Stroke vs. Warfarin

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced findings from the U.S. Food and Drug Administration's (FDA) Mini-Sentinel...

Nov 28, 2017, 07:00 ET Janssen and Johnson & Johnson Innovation Announce Next-Gen Baby Box QuickFire Challenge Finalists

Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Johnson & Johnson Innovation LLC, in...

Nov 14, 2017, 07:00 ET INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events

Janssen Research & Development, LLC (Janssen) today announced a new analysis from the CANVAS Program, which showed INVOKANA® (canagliflozin)...

Nov 03, 2017, 10:30 ET INVOKANA® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease

Janssen Research & Development, LLC today announced additional analyses from the landmark CANVAS clinical trial program showing INVOKANA®...

Nov 01, 2017, 10:02 ET ASH 2017: Janssen to Present 40 Abstracts, Including 8 Oral Presentations, with New Data on DARZALEX® (daratumumab), IMBRUVICA® (ibrutinib) and Other Compounds from Robust Portfolio

New data for the immunotherapy DARZALEX® (daratumumab) and first-in-class BTK inhibitor IMBRUVICA® (ibrutinib) are among eight oral presentations...